Bibliography
- RAPPUOLI R, MILLER HI, FALKOW S: The intangible value of vaccination. Science (2002) 297:937–939.
- RAPPUOLI R: Why must we pay more? New Scientist (2002) 31 August:25.
- GRFC0 M: The future of vaccines: an industrial perspective. Vaccine (2002) 20:S101–S103.
- WEBBER D, KREMER M: Perspectives onstimulating industrial research and development for neglected infectious diseases. Bull. World Health Organ. (2001) 79:735–741.
- WIDDUS R: Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull. World Health Organ. (2001) 79:713–720.
- MILLER E, SALISBURY D, RAMSAY M: Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in UK: a success story. Vaccine (2002) 20:S58–S67.
- TROTTER C, EDMUNDS WJ: Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br. Med. (2002) 324:1–6.
- WHEELER C, BERKLEY S: Initial lessonsfrom public-private partnerships in drug and vaccine development. Bull. World Health Organ. (2001) 79:728–734.